Search Submit Your Manuscript

Become A Member

  1. Home
  2. October 2023
  3. 23. Comparison of Drug Regimens (Sofosbuvir and velpatasvir versus Sofosbuvir and Daclatasvir) in Treatment of Chronic Hepatitis C Virus Patients in Terms of Efficacy and Safety
Article Image
Admin

23. Comparison of Drug Regimens (Sofosbuvir and velpatasvir versus Sofosbuvir and Daclatasvir) in Treatment of Chronic Hepatitis C Virus Patients in Terms of Efficacy and Safety

Umair Latif1, Fahad Shaheen2, Muhammad Daud3, Abbas Khan4, Akkash Haider5 and Taimur Khan6

ABSTRACT

Objective: To compare drug regimens (Sofosbuvir + velpatasvir vs Sofosbuvir + daclatasvir) in treatment of chronic HCV patients in terms of efficacy and safety.

Study Design: A descriptive study,

Place and Duration of Study: This study was conducted at the Gastroenterology Department, Hayatabad Medical Complex, Peshawar from October 2020–June 2021.

Methods: The gastrointestinal department of Hayatabad Medical Complex Peshawar conducted this descriptive research from January to September 2019. Patients were divided into two groups. Both groups A and B included 80 patients. For 12 weeks, group A received sofosbuvir and velpatasvir while group B received daclatasvir. Effectiveness was measured by SVR12 at 12 weeks after treatment. All data analysis was done in SPSS 24.

Results: In group A, 77 (96.25%) individuals had SVR 12, whereas group B had 72 (90%). In group A, 78 (97.5%) achieved ETR, whereas in group B, 74 (92.5%) did. Relapse was detected in 1 (1.25%) patient in group A and 3 (3.75%) in group B. Based on adverse events, group B had 12 (15%), 10 (12.5%), 6 (7.5%), 3 (3.75%), 2 (2.5%), 1 (1.25%), and 1 (1.25%) headache, fatigue, nausea, diarrhea, epigastric discomfort, skin rashes, and oral ulcer, while group A had 9 (11.25%), 8 (8.75%), 5 (6.25%), 1 (1.25%), 1 (1.25%), 00 (00%) and 1 (1.25%).

Conclusion: According to the results of our research, the group treated with sofosbuvir and velpatasvir had a higher sustained viral response than the group treated with sofosbuvir and daclatasvir. Compliance to therapy was comparable in both groups. Furthermore it was found that group treated with sofosbuvir and daclatasvir had a greater role of drug related adverse events.

Key Words: Efficacy; Safety; Sofosbuvir; velpatasvir; daclatasvir; chronic HCV patients

Citation of article: Latif U, Shaheen F, Daud M, Khan A, Haider A, Khan T. Comparison of Drug Regimens (Sofosbuvir and velpatasvir versus Sofosbuvir and Daclatasvir) in Treatment of Chronic Hepatitis C Virus Patients in Terms of Efficacy and Safety. Med Forum 2023;34(10):104-108.doi:10.60110/medforum.341023.